Drug Profile
Research programme: casein kinase I alpha stimulants - StemSynergy Therapeutics
Alternative Names: SST-024; SST-112mAb; SST-215; SSTC-104; SSTC3Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator StemSynergy Therapeutics
- Class Antineoplastics; Monoclonal antibodies; Small molecules
- Mechanism of Action Casein kinase Ialpha stimulants; Wnt signalling pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Synovial sarcoma
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Aug 2021 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
- 15 Jan 2018 Preclinical trials in Cancer in USA (unspecified route)